TRV-2026-1844Version 1 · Certified

Written 2026-10-18 18:13:44 UTC · current record

Reason for this version

Certified into the record

Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-1844
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-18T18:13:44.649706Z
status: published
lens: g_space
sector: health
headline: A target amplification-free CRISPR biosensor with digital microfluidic processing for microRNA profiling in AI-enhanced pediatric sepsis diagnosis
dek: MicroRNA signatures provide an informative readout of host-response dysregulation in pediatric sepsis, but their clinical translation remains limited by low target abundance and multiplexing requirements. Here, a target amplification-free CRISPR biosensing platform was established. The sensing mechanism couples Cas13a target recognition to promoter release, template reconstruction, and transcription-driven Cas13a reactivation, enabling fluorescence amplification through internal molecular cycling without amplify…
gain_title: A machine learning model trained on microRNA profiles from an automated CRISPR microfluidic platform separated sepsis from non-sepsis in 252 clinical samples with a test AUC of 0.973.
problem_title: (none)
trace_subject: (none)
gain_reading: A machine learning model trained on microRNA profiles from an automated CRISPR microfluidic platform separated sepsis from non-sepsis in 252 clinical samples with a test AUC of 0.973.
gain_evidence: In 252 clinical samples, the resulting model achieved a test-set AUC of 0.973 and an overall accuracy of 92.1%.
problem_reading: (none)
problem_evidence: (none)
quick_read: Researchers built a diagnostic platform that detects four sepsis-associated microRNAs plus a reference control without amplifying the target molecules. A digital microfluidic chip automates the reactions. The resulting profiles were fed into a machine learning model that classifies sepsis and estimates risk in children.

The work matters because microRNA signatures reflect how a child's body responds to sepsis, yet low target abundance and multiplexing needs have slowed clinical use. The evidence is early. Results come from one sample set, and the tracking of disease progression rests on a single representative case, so real-world clinical performance is still unproven.
limitation: The disease-progression finding rests on a single representative longitudinal case and is described as preliminary. The authors frame the platform only as having potential for in-vitro diagnosis, not as validated clinical practice.
tag: Evidence-backed gain
key_points: The sensing chemistry links Cas13a target recognition to promoter release and transcription-driven reactivation, amplifying the fluorescence signal rather than the target miRNA. | Four biomarkers (miR-15a, miR-21, miR-146a, miR-155) and the control snRNA U44 were detected at attomolar levels, with good specificity and minimal inter-droplet interference. | In 252 clinical samples the model reached a test-set AUC of 0.973 and 92.1% overall accuracy. | The model-derived risk score was associated with the Phoenix Sepsis Score.
rundown: The platform uses an electrowetting-based digital microfluidic chip that compartmentalizes parallel reactions. It automates droplet generation, reaction assembly, isothermal incubation, magnetic separation, and fluorescence readout.

Under optimized conditions, detection reached an expected mean input of 1.67 molecules per reaction. The microRNA profiles then served as input features for machine learning sepsis classification and risk assessment.

Beyond classification, the risk score was linked to the Phoenix Sepsis Score. In one representative longitudinal case it showed preliminary signs of tracking disease evolution. The authors describe the platform as potentially useful for in-vitro diagnosis of pediatric sepsis.
sources:
- peer_reviewed | Biosensors and Bioelectronics | https://doi.org/10.1016/j.bios.2026.119298 | 2026-10-05
prev: 0000000000000000000000000000000000000000000000000000000000000000
sha256
4b42353738ba4ee3ca8e83a3378c46f1341befb51d94a04b9d6ae2fd0f15f34d
previous
0000000000000000000000000000000000000000000000000000000000000000
Verify this record
How to verify without trusting this page

Fetch the canonical text of any version from /api/record/TRV-2026-1844 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.